




TJUH Family Medicine Resident Lecture Series
Learning Objectives
● Understand the hemostatic process including a review of the coagulation 
cascade and role of platelets in forming the platelet plug.
● Recognize mechanism of action of a variety of anticoagulant agents as 
well as indications for use and dosing.
● Improve knowledge of perioperative anticoagulation.
● Review indications & mechanisms of reversal.
● Explore indications for VTE prophylaxis in the era of COVID. 
What we won’t cover
● Cessation of anticoagulation in older adults.
● Perioperative management of medications other than anticoagulants.






● Active clot 
● Cardiac pathology
● Valve replacement/stenting
Platelet function in clot formation
● Hemostasis is achieved through three steps: 
○ Vascular spasm/vasoconstriction
○ Platelet plug formation
○ Coagulation 
● Platelet plug formation: activation, aggregation & adherence 
The Coagulation Cascade
Targets of anticoagulation: 
● Thrombin (Factor IIa)
● Protein C & S
● Factor Xa 
● Vitamin K (protein C, 
S, factors II, VII, IX, X)
PTT PT/INR
Thrombin → Fibrin → Clot
Medication/Class Mechanism of Action Adverse effects Dosing Contraindications
Warfarin 
(coumadin)
Vitamin K antagonist Major bleeding
Tissue necrosis









Factor Xa inhibitor Bruising, peripheral 
edema
30-40mg once-twice daily 
(enoxaparin)
Hx of HIT





















Bruising 75mg daily Drug intolerance 
INR targets
● INR 2.0 - 3.0 
● Exceptions: 
○ Aortic mechanical valve + risk factors (a fib, prior thromboembolism, hypercoagulable 
conditions, LV dysfunction)
○ Mechanical mitral valve → 2.5 - 3.5
INR Goal
Does the patient 
have a mechanical 
heart valve? 
Yes No
Mitral Aortic INR 2.0 - 3.0





Yes NoINR 2.5 - 3.5 INR 2.0 - 3.0










Medication/Class Mechanism of Action Adverse effects Dosing Contraindications
Warfarin 
(coumadin)
Vitamin K antagonist Major bleeding
Tissue necrosis









Factor Xa inhibitor Bruising, peripheral 
edema
30-40mg once-twice daily 
(enoxaparin)
Hx of HIT

























KF is a 76 yo M with PMHx of HLD, HTN who recently was hospitalized 
following a fall on the ice and resulting hip fracture. He presented to the 
emergency department with left calf swelling that he noticed starting 2-3 days 
ago. HR 80s, BP 120/78, O2 99% on room air. EKG with normal sinus rhythm. 
Venous dopplers positive for DVT. According to the 2016 CHEST guidelines, 







● DOACs - first line treatment of non-cancer associated provoked or 
unprovoked VTE over vitamin K antagonists (2B) or LMWH (2C) 
● LMWH - first line treatment of cancer-associated provoked or unprovoked 
VTE over DOACs (2C) or vitamin K antagonists (2B)
● Low-risk patients with subsegmental PE do not always require 
anticoagulation 
2014/2016 ACC/AHA Guidelines on ASA/DAPT
● ASA
○ Heart valve replacement (mechanical or bioprosthetic)
○ Primary prevention of CVD
○ Secondary ischemic stroke prevention
● DAPT
○ Bare metal stents → 1 month
○ Coronary artery stenting (DES) → 6 months
○ Stenting after MI → 12 months 
Perioperative anticoagulation
Case 2
DJ is a 64 yo F with PMHx of T2DM, atrial fibrillation on eliquis, HTN, HLD, 
bilateral knee osteoarthritis that you see in clinic for her annual physical exam 
and pre-op clearance. How long (ideally) should DJ’s eliquis be held prior to 
this elective procedure?
A) 24 hours
B) 48 hours 
C) 72 hours
D) It should be continued through the procedure 
Perioperative anticoagulation
● Recommendation is to delay elective surgery if: 
○ Less than 6 months since PCI/DES
○ Less than 12 months since ACS
○ Less than 3 months since stroke 
● Assess procedural bleeding risk
○ Low → continue anticoagulation & ASA





● DOACs should be held for 48hr prior to surgery 
○ Neuraxial anesthesia - 72hr due to risk for spinal hematoma 
● Aspirin/anti-platelet agents
○ Hold 5-7 days prior to surgery 
○ If prior PCI/DES > 6 months → continue ASA through procedure
○ If prior PCI/DES < 6 months → ASA monotherapy, resume plavix ASAP following 
procedure
● Coumadin
○ Hold for 5 days prior to OR
● LMWH/unfractionated heparin (bridging)
○ Hold ~24hr prior to OR/hold 4-5hr prior to OR 
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DOAC - Low bleeding risk
DOAC - High bleeding risk
To Bridge or not to Bridge
● Do not bridge atrial fibrillation (2015 BRIDGE)
○ Exceptions: CHA2DS2Vasc 7+ or embolic event within 3 months
● Mechanical valves warrant bridging (2014 ACC guidelines) 
○ Exceptions: low risk aortic valves 
● Do not bridge DOACs (2018 PAUSE)
● Do not always need to bridge prior VTE
● Recent VTE or stroke (within 3 months) 
● Active malignancy
● Severe thrombophilia (antiphospholipid antibody syndrome) 
● Mechanical valve
● Atrial fibrillation with high CHA2DS2Vasc
Resumption of anticoagulation (post-procedure)
● Coumadin
○ Resume the evening of/day after surgery (12-24hr) and monitor INR
○ Requires a minimum of 5 days of overlap with parenteral anticoagulants (heparin/LMWH)
■ Monitor until INR is in targeted therapeutic range for >24hr 
● LMWH/unfractionated heparin - therapeutic
○ Resume 24hr after surgery
● DOACs provide more immediate anticoagulation 
○ Resume 24hr after surgery 
One additional consideration - Neuraxial Anesthesia
● Prophylactic-dose LMWH 
○ Wait at least 10-12hr after last dose of lovenox for placement of epidural
○ Wait at least 6-8hr after epidural catheter removal to resume 
● Therapeutic-dose LMWH
○ Wait at least 24hr after last dose of lovenox for placement of epidural
○ Wait at least 24hr after epidural catheter removal to resume 
Reversal
Case 3
WJ is a 68 year old male with PMHx of ESRD on HD, valvular atrial fibrillation 
on coumadin who was sent in by his outpatient coumadin clinic for a 
supratherapeutic INR and concern for rectal bleeding at home. In the ED, EKG 
confirms that he is in atrial fibrillation with HR 110s, BP 130/80s. FOBT is 
negative, you note external hemorrhoids on exam. INR repeated in the ED: 
5.2. What next step would you take? 
A) Hold today’s dose, repeat INR overnight
B) IV Vitamin K, repeat INR 
C) PO Vitamin K, repeat INR
D) FFP, repeat INR
Indications for reversal
● In patients without significant bleeding
○ INR supratherapeutic but <4.5 → decrease/hold dose, resume at lower dose
○ INR 4.5 - 10 → hold 1-2 doses, resume at lower dose 
○ INR >10 → hold dose, administer vitamin K (PO), resume at lower dose
● In patients with concern for bleeding, options include: 
○ PO/IV vitamin K
○ FFP
○ Recombinant Factor VIIa 
○ Prothrombin complex concentrate (PCC - 3F & 4F)
○ Factor VIII inhibitor bypass activity
Reversal of warfarin-induced bleed
Reversal agents
● Heparin/LMWH
○ Protamine (unfractionated heparin > LMWH)
● Reversal in DOACs
○ Idarucizumab → dabigatran
○ Andexxa (andexanet alpha) → rivaroxaban & apixiban 
Anticoagulation in COVID
Case 4
JR is a 32yo M with no significant PMHx who was hospitalized for COVID PNA. 
His oxygen requirement decreases during his hospitalization and he is stable 
for discharge. He has been reading Dr. Haines’ book during his hospitalization 
and while getting ready for discharge, he asks whether he needs VTE 
prophylaxis after leaving the hospital. What do you think? 
A) Sure
B) Not indicated 
Anticoagulation in COVID
Anticoagulation in COVID
How this should change our practice
● Bleeding risk assessment should be performed at each visit for patients 
on anticoagulation.
● When discussing medications on hospital discharge - consider DOACs 
over coumadin. 
● Communicate with surgical teams - particularly during visits for pre-op 
clearance and keep an open line of communication with surgical consult 
teams while in the hospital.
● Communicate with pharmacy to appropriately adjust dosing for kidney 
function. 
Take Home Points
● Anticoagulation, both inpatient & outpatient, requires careful patient 
monitoring and follow up is important! 
● Monitor for changes to a patient’s medication list.
● There is no one-size-fits-all when it comes to decisions for perioperative 
anticoagulation.
● Consider VTE prophylaxis in COVID patients when discharging from the 
hospital.
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● Vitamin K antagonist
● Indications:
○ Valvular atrial fibrillation, mechanical valve
● Contraindications: 
○ Pregnancy
○ Unsupervised & potentially noncompliant patients
● Adverse effects:
○ Tissue necrosis (<0.1%), compartment syndrome
○ Major bleeding (<5%)
Heparin (unfractionated)
● Inactivates thrombin, prevents conversion of fibrinogen to fibrin 
● Indications:
○ Anticoagulation in CKD/HD patients, ACS, bridging 
● Contraindications: 
○ Severe thrombocytopenia, history of HIT
○ Recommend not to initiate drip if appropriate levels cannot be monitored
● Adverse effects: 
○ Thrombocytopenia (+/- HIT)
Low-molecular weight heparin (ex: lovenox)
● Factor Xa inhibitor
● Indications:  
○ Active malignancy, VTE
● Contraindications: 
○ History of HIT
○ CrCl < 15 mL/min
● Adverse effects: 
○ Peripheral edema 
Direct oral anticoagulants (dabigatran)
● Direct thrombin inhibitor 
● Indications:
○ Non-valvular atrial fibrillation, DVT/PE (tx & prophylaxis), stroke prevention
● Contraindications: 
○ Drug intolerance
● Adverse effects: 
○ Bruising
Direct oral anticoagulants (apixaban, rivaroxaban)
● Inhibition of factor Xa
● Indications for use: 
○ Non-valvular atrial fibrillation, DVT/PE (tx & prophylaxis), stroke prevention
● Contraindications: 
○ Drug intolerance
● Adverse effects: 
○ Bruising
Aspirin
● Inhibits COX-1 & 2 enzymatic activity; inhibits formation of thromboxane 
A2 which inhibits platelet aggregation
● Indications for use: 
○ ACS, TIA, colorectal cancer, preeclampsia, heart valve
● Contraindications: 
○ Drug intolerance 
● Adverse effects: 
○ GI bleed, ASA sensitivity, Reye’s syndrome, renal insufficiency
Plavix (clopidogrel)
● Inhibition of platelet aggregation




● Adverse effects: 
○ Bruising
